NUVECTIS PHARMA INC (NVCT)
US67080T1088 - Common Stock
NVCT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. While NVCT seems to be doing ok healthwise, there are quite some concerns on its profitability. NVCT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year NVCT has reported negative net income.
In the past year NVCT has reported a negative cash flow from operations.
1.2 Ratios
NVCT has a worse Return On Assets (-111.94%) than 78.99% of its industry peers.
NVCT's Return On Equity of -176.27% is on the low side compared to the rest of the industry. NVCT is outperformed by 67.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -111.94% | ||
| ROE | -176.27% | ||
| ROIC | N/A |
ROA(3y)-134.37%
ROA(5y)N/A
ROE(3y)-206.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NVCT has more shares outstanding than it did 1 year ago.
There is no outstanding debt for NVCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
NVCT has an Altman-Z score of 1.37. This is a bad value and indicates that NVCT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NVCT (1.37) is better than 67.68% of its industry peers.
There is no outstanding debt for NVCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.37 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.74 indicates that NVCT has no problem at all paying its short term obligations.
With a Current ratio value of 2.74, NVCT is not doing good in the industry: 68.40% of the companies in the same industry are doing better.
NVCT has a Quick Ratio of 2.74. This indicates that NVCT is financially healthy and has no problem in meeting its short term obligations.
NVCT has a worse Quick ratio (2.74) than 66.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.74 | ||
| Quick Ratio | 2.74 |
3. Growth
3.1 Past
NVCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.38%, which is quite impressive.
EPS 1Y (TTM)21.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 7.55% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.1%
EPS Next 2Y15.1%
EPS Next 3Y7.55%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NVCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.1%
EPS Next 3Y7.55%
5. Dividend
5.1 Amount
NVCT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NUVECTIS PHARMA INC
NASDAQ:NVCT (1/3/2025, 8:00:02 PM)
5.58
+0.19 (+3.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners11.42%
Inst Owner Change-13.95%
Ins Owners53.26%
Ins Owner Change0.97%
Market Cap107.81M
Analysts84.44
Price Target22.44 (302.15%)
Short Float %15.42%
Short Ratio7.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.36%
Min EPS beat(2)1.96%
Max EPS beat(2)6.75%
EPS beat(4)3
Avg EPS beat(4)9.2%
Min EPS beat(4)-10.13%
Max EPS beat(4)38.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)34.29%
EPS NY rev (1m)0%
EPS NY rev (3m)3.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.81 | ||
| P/tB | 9.81 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.16
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS0.57
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -111.94% | ||
| ROE | -176.27% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-134.37%
ROA(5y)N/A
ROE(3y)-206.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.74 | ||
| Quick Ratio | 2.74 | ||
| Altman-Z | 1.37 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
EPS Next Y28.1%
EPS Next 2Y15.1%
EPS Next 3Y7.55%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.23%
EBIT Next 3Y-5.78%
EBIT Next 5YN/A
FCF growth 1Y-17.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.65%
OCF growth 3YN/A
OCF growth 5YN/A